PR Newswire
LAS VEGAS, Feb. 9, 2026
The invasive fungal infections market is expected to grow by 2034, owing to the approval of new agents such as Ibrexafungerp (Glaxosmithkline/SCYNEXIS), Fosmanogepix (Basilea Pharmaceutica), Olorofim (F901318) (Shionogi/F2G), Opelconazole (PC945) (Pulmocide), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with IFIs.
LAS VEGAS, Feb. 9, 2026 /PRNewswire/ — DelveInsight’s Invasive Fungal Infections Market Insights report includes a comprehensive understanding of current treatment practices, invasive fungal infections emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Invasive Fungal Infections Market Summary
- According to DelveInsight’s analysis, the market size for invasive fungal infections was found to be USD 350 million in the US in 2024.
- In the United States, the burden of invasive fungal infections is estimated at approximately 110,000 cases in 2024 and is projected to increase during the forecast period (2025-2034).
- Invasive candidiasis and aspergillosis form the largest group of opportunistic IFIs, primarily affecting immunocompromised populations, together contributing around 50% of the total burden.
- Several leading pharmaceutical and biotechnology companies including Glaxosmithkline, SCYNEXIS, Basilea Pharmaceutica, Shionogi, F2G, Pulmocide, Mycovia Pharmaceuticals, Matinas BioPharma, Biosergen, Elion Therapeutics, and others, are actively engaged in the development of emerging therapies for invasive fungal infections. These organizations are advancing novel antifungal agents that are anticipated to expand treatment options and contribute to the growth of the invasive fungal infections market in the coming years..
- The promising invasive fungal infections therapies in clinical trials include BREXAFEMME (ibrexafungerp), Fosmanogepix, Olorofim (F901318), Opelconazole (PC945), Oteseconazole (VT-1161), MAT2203, SCY-247, BAL2062, BSG005, EL219 (SF001), and others.
- As per DelveInsight’s analysis, by 2034, among the emerging therapies, the highest revenue is expected to be generated by fosmanogepix in the United States.
Discover the new invasive fungal infections treatment @ https://www.delveinsight.com/sample-request/invasive-fungal-infections-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Invasive Fungal Infections Market
- Rising Invasive Fungal Infections Burden: The global burden of invasive fungal infections has continued to rise in line with the expanding population at risk. In the United States, the burden is estimated at approximately 110,000 cases in 2024 and is projected to increase during the forecast period (2025-2034).
- CRESEMBA (isavuconazonium sulfate) Dominates the Invasive Fungal Infections Market: CRESEMBA leads the invasive fungal infections market, capturing approximately 45% share, highlighting its dominance among existing oral and IV therapies.
- Emerging Antifungal Drug Classes: Key candidates include BREXAFEMME (ibrexafungerp) (oral triterpenoid, effective against azole- and echinocandin-resistant Candida), fosmanogepix (Gwt1 inhibitor with broad activity against resistant yeasts and molds), olorofim (DHODH inhibitor for azole-resistant Aspergillus), opelconazole (inhaled azole targeting pulmonary infections), and MAT2203 (oral Amphotericin B with reduced toxicity).
-
First Mover Advantage for BREXAFEMME
(ibrexafungerp)
: In the emerging landscape, BREXAFEMME is poised to maintain first-mover advantage in invasive fungal infections despite fosmanogepix addressing a broader patient population, owing to its prior approval for Vulvovaginal Candidiasis (VVC) and established clinical footprint, while opelconazole represents the first inhalation-based antifungal, with the potential to enhance patient compliance compared with conventional oral or IV therapies.
Invasive Fungal Infections Market Analysis
- Treating invasive fungal infections remains a significant challenge due to the limited number of drug classes, increasing resistance, and safety concerns.
- Current therapies primarily include azoles, echinocandins, polyenes, and 5-FC, yet the emergence of multidrug-resistant strains such as Candida auris, Candida glabrata, and azole-resistant Aspergillus fumigatus is undermining their effectiveness.
- The expansion of the invasive fungal infections market is driven by advances in diagnostics, broader use of prophylaxis in high-risk populations, and innovation in antifungal drug design and delivery.
- Late-stage candidates like fosmanogepix, ibrexafungerp, and olorofim are poised to transform treatment paradigms through novel mechanisms, oral availability, and activity against resistant pathogens.
- Despite advances, challenges such as toxicity, drug-drug interactions, and persistent resistance highlight ongoing unmet needs, positioning the market as one of cautious advancement with next-generation therapies expected to play a critical role.
Invasive Fungal Infections Competitive Landscape
The IFIs pipeline possesses several candidates currentlyin mid- and late-stage developments to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Ibrexafungerp (Glaxosmithkline/SCYNEXIS), Fosmanogepix (Basilea Pharmaceutica), Olorofim (F901318) (Shionogi/F2G ), Opelconazole (PC945) (Pulmocide), and others.
Glaxosmithkline/SCYNEXIS’ Ibrexafungerp is the first drug in a novel class of structurally unique glucan synthase inhibitors called triterpenoids. It exhibits broad-spectrum antifungal activity against diverse pathogens, including Candida, Aspergillus, Pneumocystis, dimorphic fungi, and mucorales, and is effective even against multidrug-resistant (MDR) and pan-resistant strains such as Candida auris. The drug is already approved for treating Vulvovaginal Candidiasis (VVC) and is currently being evaluated in a Phase III clinical trial (NCT05178862) for invasive candidiasis and other difficult-to-treat fungal infections.
Basilea Pharmaceutica’s Fosmanogepix is a first-in-class, broad-spectrum antifungal in clinical development that inhibits the fungal enzyme Glycosylphosphatidylinositol-anchored wall transfer Protein 1 (Gwt1), a critical component for cell wall integrity and fungal survival. This unique mechanism allows it to act against a wide range of pathogens, including Candida species (notably C. auris and azole-resistant strains), Aspergillus, Fusarium, Scedosporium, rare molds, and endemic fungi.
The anticipated launch of these emerging therapies are poised to transform the invasive fungal infections market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the invasive fungal infections market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the invasive fungal infections drugs market @ Invasive Fungal Infections Drugs
Recent Developments in the Invasive Fungal Infections Market
- In July 2025, Basilea received USD 39 million in funding under the BARDA agreement to continue to advance novel antifungal fosmanogepix.
- In May 2025, SCYNEXIS announced that the first new patient was dosed in the Phase III MARIO study following the lifting of the FDA clinical hold.
- In April 2025, BAL2062 has recently completed its Phase I clinical trial, with preparations currently underway for the initiation of the Phase II study, anticipated to commence in 2026.
- In February 2025, Biosergen reported the successful completion of treatment for the second cohort of patients in its proof-of-concept clinical trial for BSG005.
What are Invasive Fungal Infections?
Invasive fungal infections are serious diseases marked by the penetration of fungal pathogens into normally sterile areas of the body, such as deep tissues and vital organs, often resulting in prolonged illness and potentially fatal complications. These infections primarily occur in individuals with compromised immune systems, including those receiving chemotherapy, people living with HIV/AIDS, or organ transplant recipients on immunosuppressive drugs. The main causative agents include Candida species (notably Candida albicans, C. glabrata, C. tropicalis), Aspergillus species (especially Aspergillus fumigatus), Cryptococcus species, and various dimorphic fungi. Typically, these fungi are opportunistic organisms, normally harmless residents of the environment or human microbiota, that turn pathogenic when the host’s immune defenses are weakened.
Invasive Fungal Infections Epidemiology Segmentation
The invasive fungal infections epidemiology section provides insights into the historical and current invasive fungal infections patient pool and forecasted trends for the leading markets. Approximately, 90% of patients develop resistance to first-line antifungal therapy, necessitating therapy modification. Among these, nearly 30% also develop resistance to second-line agents, forcing switches within drug classes (e.g., azoles) or across classes (e.g., from azoles to echinocandins or polyenes).
The invasive fungal infections treatment market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
- Total Incident Cases of Invasive Fungal Infections
- Total Incident Cases of Invasive Fungal Infections by Type
- Total Treatment-eligible Cases of Invasive Fungal Infections
- Total Refractory Cases of Invasive Fungal Infections
Invasive Fungal Infections Market
Report Metrics
Details
Study Period
2020-2034
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) the United Kingdom, and
Japan].
Invasive Fungal Infections Market
CAGR
11.4% (US)
Invasive Fungal Infections Market
Size in 2024 (US)
USD 350 Million
Key Invasive Fungal Infections Glaxosmithkline, SCYNEXIS, Basilea Pharmaceutica, Shionogi, F2G, Pulmocide, Mycovia
Companies Pharmaceuticals, Matinas BioPharma, Biosergen, Elion Therapeutics, Cidara Therapeutics,
Mundipharma, Astellas Pharma, Pfizer, Vicuron Pharmaceuticals, Mayne Pharma, Merck, and others
Key Invasive Fungal Infections BREXAFEMME (ibrexafungerp), Fosmanogepix, Olorofim (F901318), Opelconazole (PC945), Oteseconazole
Therapies (VT-1161), MAT2203, SCY-247, BAL2062, BSG005, EL219 (SF001), REZZAYO (rezafungin), CRESEMBA
(isavuconazonium sulfate), ERAXIS (anidulafungin), TOLSURA (itraconazole), NOXAFIL
(posaconazole), and others
Scope of the
Invasive Fungal Infections
Market Report
- Therapeutic Assessment: Invasive Fungal Infections current marketed and emerging therapies
- Invasive Fungal Infections Market Dynamics: Key Market Forecast Assumptions of Emerging Invasive Fungal Infections Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Invasive Fungal Infections Market Access and Reimbursement
Download the report to understand the factors driving the invasive fungal infections market @ Invasive Fungal Infections Market Analysis
Table of Contents
1
Invasive Fungal Infections Market Key Insights
2
Invasive Fungal Infections Market Report Introduction
3
Executive Summary
4
Key Events
4.1
Upcoming Key Catalysts
4.2
Key Conferences and Meetings
4.3
Key Transactions and Collaborations
4.4
News Flow
5
Epidemiology and Market Forecast Methodology
6
Invasive Fungal Infections Market Overview at a Glance
6.1 Clinical Landscape (Analysis by Molecule Type, Phase, and Route of
Administration [RoA])
6.2 Market Share (%) Distribution of Invasive Fungal Infections by Therapies
in 2024
6.3 Market Share (%) Distribution of Invasive Fungal Infections by Therapies
in 2034
7
Disease Background and Overview
7.1
Introduction
7.2
Common Types of Invasive Fungal Infections
7.3
Invasive Fungal Infections Causes and Risk Factors
7.3.1
Invasive Fungal Infections Risk Factors
7.4
Invasive Fungal Infections Signs and Symptoms
7.5
Complications of Invasive Fungal Infections
7.6
Invasive Fungal Infections Diagnosis
7.7
Treatment of Invasive Fungal Infections
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale
8.3
Total Incident Cases of Invasive Fungal Infections in the 7MM
8.4
Epidemiology Scenario in the US
8.4.1
Total Incident Cases of Invasive Fungal Infections in the US
8.4.2 Total Incident Cases of Invasive Fungal Infections by Type in the US
8.4.3 Total Treatment-eligible Cases of Invasive Fungal Infections in the US
8.4.4 Total Refractory Cases of Invasive Fungal Infections in the US
8.5
Epidemiology Scenario in EU4 and the UK
8.6
Epidemiology Scenario in Japan
9
Invasive Fungal Infections Patient Journey
10
Marketed Invasive Fungal Infections Drugs
10.1
Key Cross of Marketed Drugs
10.2
REZZAYO (rezafungin): Cidara Therapeutics/Mundipharma
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Summary of Pivotal Trial
10.2.5
Clinical Development
10.2.5.1
Clinical trials information
10.2.6
Analyst Views
10.3 CRESEMBA (isavuconazonium sulfate): Basilea Pharmaceutica /Astellas
Pharma
10.4
ERAXIS (anidulafungin): Pfizer/Vicuron Pharmaceuticals
10.5
TOLSURA (itraconazole): Mayne Pharma
10.6
NOXAFIL (posaconazole): Merck
11
Emerging Invasive Fungal Infections Drugs
11.1
Key Cross Competition
11.2
BREXAFEMME (Ibrexafungerp): Glaxosmithkline/SCYNEXIS
11.2.1
Product Description
11.2.2
Other Development Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trial Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
Fosmanogepix: Basilea Pharmaceutica
11.4
Olorofim (F901318): Shionogi/F2G
11.5
Opelconazole (PC945): Pulmocide
11.6
Oteseconazole (VT-1161): Mycovia Pharmaceuticals
11.7
MAT2203: Matinas BioPharma
11.8
SCY-247: SCYNEXIS
11.9
BAL2062: Basilea Pharmaceutica
11.10
BSG005: Biosergen
11.11
EL219 (SF001): Elion Therapeutics
12
Invasive Fungal Infections Market: 7MM Analysis
12.1
Key Findings
12.2
Invasive Fungal Infections Market Outlook
12.3
Key Invasive Fungal Infections Market Forecast Assumptions
12.4
Conjoint Analysis
12.5
Total Market Size of Invasive Fungal Infections in the 7MM
12.6
United States Invasive Fungal Infections Market Size
12.6.1 Total Market Size of Invasive Fungal Infections in the United States
12.6.2 Market Size of Invasive Fungal Infections by Therapies in the United
States
12.7
EU4 and the UK Invasive Fungal Infections Market Size
12.8
Japan Invasive Fungal Infections Market Size
13
Invasive Fungal Infections Market Unmet Needs
14
Invasive Fungal Infections Market SWOT Analysis
15
KOL Views on Invasive Fungal Infections
16
Invasive Fungal Infections Market Access and Reimbursement
17
Bibliography
18
Invasive Fungal Infections Market Report Methodology
Related Reports
Candidiasis Market
Candidiasis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key candidiasis companies including Cidara Therapeutics, MATINAS BIOPHARMA HOLDINGS, ProFem GmbH, CelaCare Technologies, Inc., SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, Mycovia Pharmaceuticals, ORYN THERAPEUTICS, Biocidium Biopharmaceuticals, Hyloris Pharmaceuticals, among others.
Candidiasis Clinical Trial Analysis
Candidiasis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key candidiasis companies, including Cidara Therapeutics, MATINAS BIOPHARMA HOLDINGS, ProFem GmbH, CelaCare Technologies, Inc., SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, Mycovia Pharmaceuticals, ORYN THERAPEUTICS, Biocidium Biopharmaceuticals, Hyloris Pharmaceuticals, among others.
Invasive Pneumococcal Disease Market
Invasive Pneumococcal Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key invasive pneumococcal disease companies including Pfizer, Merck, Wyeth Pharmaceuticals, GlaxoSmithKline, Merck Sharp & Dohme Corp, Affinivax, Astellas Pharma, Vaxcyte, ImmunoBiology Ltd., Merck Sharp & Dohme Corp, EuBiologics, among others.
DHODH Inhibitors Market
DHODH Inhibitors Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key DHODH inhibitors companies, including Immunic Therapeutics, Jabez Bioscience, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/invasive-fungal-infections-market-to-witness-upsurge-in-growth-at-a-cagr-of-11-4-in-the-us-during-the-forecast-period-20252034–delveinsight-302682266.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…